Experimental drug aims to protect hearts during major attacks
NCT ID NCT07091929
Summary
This early-stage study tested a new drug called SGC001 in 38 Chinese patients who had just suffered a severe type of heart attack (anterior STEMI). The main goal was to check if the drug is safe and to find the right dose for future studies. Researchers also looked for early signs that the drug might help reduce the amount of heart muscle damage and inflammation after the attack.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTERIOR MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Anzhen Hospital Capital Medical University
Beijing, Beijing Municipality, 100013, China
-
Linfen Central Hospital
Linfen, Shanxi, 041099, China
-
Teda International Cardiovascular Hospital
Tianjin, Tianjin Municipality, 300457, China
-
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150086, China
Conditions
Explore the condition pages connected to this study.